Medical Aesthetics: A Untapped Pharma Market With Incoming Competition
Medical aesthetics is a unique biopharmaceutical niche that may scare off companies due to the consumer marketing and doctor relationship-building skills needed to compete in this market, but the potential for growth keeps major players engaged and searching for new technology.
You may also be interested in...
Allergan declared that no other brand is more 'iconic' than Botox, during its medical aesthetics investor event, but the company also revealed several defensive moves to protect the neurotoxin's status, including the acquisition of fast-acting, short duration toxin maker Bonti.
The drug has become the only neurotoxin to be approved for excessive drooling in the US, giving Merz an advantage over rivals such as Allergan's Botox to treat a condition that affects over 600,000 adults across the Atlantic.
Phase III data show statistically significant wrinkle-reducing results for up to six months across two trials for Revance's neuromodulator RT002. With a safety study ongoing, the Botox competitor isn't likely to hit the market until 2020, but it's yet another piece of bad news for Allergan.